Web31 aug. 2024 · Medtronic has completed the acquisition of Affera. This acquisition expands the company's cardiac ablation portfolio to include its cardiac mapping and navigation platform. The investigational Affera technology is designed to provide solutions for patients with cardiac arrhythmias (irregular heartbeats) such as atrial fibrillation (AF). Through ... Web15 mrt. 2024 · The Affera Mapping and Ablation System will be commercially available beginning in the first half of 2024 in Europe and is investigational in the United States. …

Medtronic

Web11 jan. 2024 · Medtronic plc (MDT Quick Quote MDT - Free Report) recently made a major investment to advance in the prospering field of electrophysiology (EP).The company entered into a definitive agreement to ... Web2 sep. 2024 · DUBLIN, Aug. 30, 2024. Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Affera, Inc. This acquisition expands the company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform that encompasses a differentiated, fully … how does anaphase 11 differ from anaphase 1

Medtronic receives CE Mark approval for Affera™ Mapping and …

Web11 jan. 2024 · For investors’ note, Medtronic, through its minority investment portfolio, has been a strategic investor in Affera and already holds a 3% ownership stake in the company. WebAffera started in 2014 with a simple goal that paid off when Medtronic (NYSE:MDT) bought the company for up to $1 billion this year. Achieving that goal, however, took some unconventional and sometimes difficult design choices, Affera founder and … Web16 mrt. 2024 · Medtronic receives CE Mark approval for Affera™ Mapping and Ablation System to treat atrial arrhythmias. First of its kind, all-in-one Sphere-9™ Catheter with … how does anaphase ii differ from anaphase